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Background: For many years, surgery has been the standard treat-
ment for patients with early-stage non-small cell lung cancer
(NSCLC). Recent randomized trials demonstrated that cisplatin-
based adjuvant chemotherapy increases overall survival. The aim of
this study was to analyze the precise use of adjuvant chemotherapy
in patients with resected NSCLC in routine practice.
Patients and Methods: Between January 2004 and May 2005, we
retrospectively analyzed 219 patients with early-stage NSCLC who
had undergone surgery at one major surgical center in Paris, Institut
Mutualiste Montsouris. Patient characteristics, the type of surgery,
and indications for adjuvant chemotherapy were analyzed.
Results: Eighty-seven of the 219 patients (40%) in this study had
been treated with adjuvant chemotherapy. Different factors were
associated with doctors not prescribing this treatment: age, comor-
bidity, tumor, node, metastasis stage, and postoperative complica-
tions. More than eight different cisplatin-based regimens were used,
highlighting considerable heterogeneity in the use of adjuvant che-
motherapy in daily practice. There is an increase of adjuvant
chemotherapy during the study period.
Conclusion: Cisplatin-based chemotherapy is the standard treat-
ment for patients with resected stage II and IIIA NSCLC. However,
such therapy is used quite heterogeneously in daily practice and
specific regimens, and the percentage of patients receiving adjuvant
chemotherapy vary from standard recommendations. A prospective
follow-up of daily practice regarding the use of adjuvant chemo-
therapy is warranted.
Key Words: Non-small cell lung cancer, Adjuvant chemotherapy,
Guidelines.
(J Thorac Oncol. 2009;4: 1504–1510)
Lung cancer is the leading cause of cancer-related death inthe developed world. Of the 1.2 million new cases of lung
cancer that are diagnosed annually, approximately 1 million
patients will die.1,2 Non-small cell lung cancer (NSCLC) is
the most common type of lung cancer accounting for 80% of
the cases. One third of patients with NSCLC present with
early-stage disease that is amenable to potentially curative
resection and adjuvant therapy.
The prognosis of NSCLC depends on the disease stage,
but even in cases of stage I disease, approximately one third
of patients will die of their malignancy within 5 years with
systemic recurrence rates ranging from 55 to 75%. The risk of
local recurrence after complete resection is in fact quite low,
but the majority of these relapses is distant metastases.3
Theoretically, postoperative chemotherapy is scheduled to
eliminate occult metastases and improve overall survival.4
Adjuvant chemotherapy is the standard treatment of
different cancers such as breast cancer and colon cancer and
has clearly improved overall survival.5,6
The first trials of postoperative adjuvant chemotherapy
for NSCLC showed that alkylating agents and older chemo-
therapies were detrimental to survival.7,8 Randomized trials
of postoperative cisplatin-based chemotherapy subsequently
failed to show any individually relevant benefit.9 An individ-
ual patient data-based meta-analysis of data from these stud-
ies was published in 1995.7 Eight trials used cisplatin doses of
50 to 240 mg/m2 (total dose) diversely combined with doxo-
rubicin, cyclophosphamide, or vindesine. The analysis found
that this chemotherapy yielded a 13% reduction in the risk of
death (an overall hazard ratio of 0.87 [p  0.08]); the
absolute benefit of chemotherapy was 3% at 2 years (95%
confidence interval [CI], 0.5% detriment to 7% benefit) and
5% at 5 years (95% CI, 1% detriment to 10% benefit), but the
results were not statistically significant. Nevertheless, they
led to adjuvant cisplatin-based chemotherapy trials in com-
pletely resected NSCLC. The International Adjuvant Lung
Cancer Collaborative Group Trial (IALT) is the largest study
of adjuvant chemotherapy conducted to date and was the first
trial to demonstrate a benefit for adjuvant cisplatin-based
chemotherapy in NSCLC.10 Patients were randomly assigned
after surgery to receive either three to four cycles of cisplatin-
based chemotherapy or for observation. The IALT study
enrolled 1,867 patients with IA to IIIB stage NSCLC. At least
74% of the patients received 240 mg/m2 of cisplatin. In more
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than half of the patients, this regimen was combined with
etoposide (56.5%) or vinorelbine (26.8%). Seven patients
(0.8%) died of chemotherapy-induced toxicity. With a fol-
low-up of 56 months, a statistically significant improvement
was achieved in overall survival with an absolute difference
of 4.1% at 5 years (overall survival 44.5% versus 40.4%)
favoring adjuvant chemotherapy. Adjuvant chemotherapy
became the new standard of care for patients with early-
stage NSCLC after the presentation of the IALT trial at the
American Society of Cancer Oncology Meeting in 2003 and
its publication in the New England Journal of Medicine in
2004. Several other trials demonstrated also the benefit of
adjuvant chemotherapy.11,12 The last pooled analysis (lung
adjuvant cisplatin évaluation) confirmed the benefit of cispla-
tin-based adjuvant chemotherapy.13
The aim of our study was to evaluate, immediately after
the positive results of the IALT report in the New England
Journal of Medicine, real compliance and the specific che-
motherapeutic regimes used for adjuvant chemotherapy in
patients after resection of NSCLC. To do so, we retrospec-
tively reviewed all the charts of patients with early NSCLC
who had undergone a complete resection in a major thoracic
surgical center in Paris, between January 2004 and May 2005.
PATIENTS AND METHODS
Patients
We retrospectively reviewed all patients diagnosed
with NSCLC and who had undergone surgery at the Institut
Mutualiste Montsouris between January 1, 2004, and May 31,
2005. The hospital information system and medical records
were used to collect patient data. During that period, 366
patients were hospitalized for thoracic surgery at the Institut
Mutualiste Montsouris. Only 219 of 366 patients had a
complete resection of early-stage NSCLC without preopera-
tive chemotherapy. Treatment and disease in other patients
were as follows: 69 patients were treated with neoadjuvant
chemotherapy, 21 patients were treated for a mediastinal
tumor, 30 patients were treated for lung metastases, 10
patients had small cell lung cancer, six patients had nonpri-
mary lung cancer, eight patients had nonmalignant diseases,
and data were missing in three patients.
Variables
The following variables were collected from the med-
ical charts: patient characteristics (age and gender), primary
medical center, treatment period, medical history (cardiovas-
cular, pulmonary, and other cancers), tobacco consumption,
and tumor characteristics (histology, type of surgery, tumor,
node, metastasis [TNM] stage, and postoperative complica-
tions). The TNM classification used for staging NSCLC was
the International System for Staging Lung Cancer revised
criteria described by Mountain.14
Postoperative Treatment
All surgical resections had been performed in the Tho-
racic Surgery Department of Institut Mutualiste Montsouris.
The patients had been treated and followed up by different
physicians in different medical centers. Data regarding adju-
vant chemotherapy were collected from the medical charts:
type of regimen, number of cycles, severe toxicities, early
interruption, locoregional and distant relapse, and death.
Statistical Analysis
All variables and patient characteristics were analyzed
with SAS. The correlation between patient characteristics and
the indication for adjuvant chemotherapy was evaluated with
a logistic regression model adjusted on age, gender, treatment
period, type of surgery, histology, tumor size, postoperative
complications, stage, and TNM N status. Correlation between
clinical factors and adjuvant chemotherapy was determined
by univariate analysis using the 2 test and the Cochran-
Armitage tendency test. A multivariate analysis that included
the significant variables in the univariate analysis was per-
formed. All reported p values are two sided. Differences were
considered statistically significant when p  0.05.
RESULTS
Patient Characteristics
Between January 2004 and May 2005, 219 patients
underwent a complete resection for early-stage NSCLC. Pa-
tient baseline characteristics are shown in Table 1.
Median age was 61 years (26–87 years), and 30.6% of
patients (67 patients) were older than 70 years.
Histologic types were as follows: 32% (70/219) squa-
mous cell carcinoma, 45% (98/219) adenocarcinoma, and
23.3% (51/219) other tumor types. The TNM stages were as
follows: 44 stage IA (20%), 71 stage IB (33%), 10 stage IIA
(4.5%), 37 stage IIB (17%), 36 stage IIIA (16%), 18 stage
IIIB (8%), and two stage IV (1%) with lung metastases.
These two cases of stage IV were not included in analyses.
The patients had been followed up after thoracic sur-
gery either in the different centers: in three centers special-
ized in thoracic oncology (63%) or in community-based
practices (37%). Eighty-eight percent of patients (193 of 219
patients) were smokers, 41% (91 of 219 patients) had cardio-
vascular diseases (high blood pressure, myocardial infarc-
tions, etc.), and 12% (26 of 219 patients) had tobacco-related
noncancer diseases (chronic respiratory insufficiency and
chronic obstructive pulmonary disease).
Treatment
Surgery
All 219 patients had undergone complete curative tho-
racic surgery: a pneumonectomy in 19% (41 patients), a
lobectomy in 68% (150 patients), and a wedge resection in
13% (28 patients) (Table 2).
During the postoperative period, the median hospital
stay was 8 days (2–85 days). Complications had been docu-
mented in 87 patients (40%) with particular infection (35
patients), acute renal failure (19 patients), hemorrhage
(eight), fistula (three patients), and empyema (two patients).
Adjuvant Chemotherapy
Eighty-seven of the 219 patients in our population had
received adjuvant chemotherapy (40% of patients). There are
15 missing data for adjuvant chemotherapy, and two cases of
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stage IV were not included in analyses. Several reasons were
directly or indirectly mentioned in the chart for not prescrib-
ing adjuvant therapy: comorbidities (26), elderlyness (26),
postoperative complications (six), stage IA disease (34), and
patient refusal (eight).
Adjuvant Chemotherapy Regimens
More than eight different regimens had been adminis-
tered in different medical centers to the 87 patients treated
with adjuvant chemotherapy (Table 3). Six patients had not
received two cycles, seven had received only two cycles, and
35 had received three cycles. Only 33 patients had completed
all four cycles of chemotherapy. Data were missing for six
patients. Early discontinuation of chemotherapy had been due
to severe toxicities (two deaths), intercurrent illness (one
brain trauma), patient refusal (four patients), and toxicities.
Toxicity and Discontinuation of Therapy
In our study, two treatment-related death were seen:
one in a patient with febrile neutropenia and one in a patient
with renal failure. Only 25 patients (29%) experienced grade
3 or 4 toxicities: 11 (12%) hematological toxicities (two
febrile neutropenia and one blood transfusion) and 14 (16%)
nonhematological toxicities with nausea/vomiting (14 pa-
tients), acute renal failure (two patients) and central venous
infection (two).
Use of Adjuvant Chemotherapy and Explicative
Variables
This analysis is based on the data from 202 patients
because of exclusion of two patients with stage IV and
missing data on chemotherapy for some patients (15 pa-
tients). Univariate and multivariate analyses were performed
to correlate different variables and the prescribing of adjuvant
chemotherapy. In the univariate analysis, age, medical center,
comorbidity, treatment period, stage, radiotherapy, and post-
TABLE 1. Baseline Patient Characteristics
Characteristics
Number (%)
(n  219)
Sex
Male 147 (67)
Female 72 (33)
Age (yr) 61 (26–87)
60 96 (44)
60–69 56 (26)
70 67 (30)
Medical cancer center
Institut Gustave Roussy (IGR) 55 (25)
Créteil (CHIC) 36 (16)
Saint Louis (AP-HP) 43 (20)
Others 85 (39)
Histology
Adenocarcinoma 98 (45)
Squamous cell carcinoma 70 (32)
Others 51 (23)
Stagea (TNM 1997)
IA 44 (20)
IB 72 (33)
II 47 (21)
III 56 (25)
Tumor size (mm)b 35 (9–140)
4 cm 116 (60)
4 cm 75 (40)
Tobaccoa 193 (88)
Cardiovascular pathologya 91 (41)
Chronic obstructive pulmonary disease (COPD) 26 (12)
Previous cancer 65 (30)
Tobacco-related cancer (lung, head and neck, and
bladder)
25 (11)
Breast cancer 9 (4)
TNM, tumor, node, metastasis.
a One missing data.
b Twenty-eight missing data.
TABLE 2. Treatment
Number (%)
(n  219)
Time between IALT publication and surgery 291 (4–537)
6 mo 75 (34)
6 mo and 1 yr 66 (30)
1 yr 78 (36)
Surgerya
Lobectomy  wedge 150 (68)
Pneumonectomy  wedge 41 (19)
Wedge 28 (13)
Time between surgery and dischargedb 8 (2–85)
8 d 113 (54)
8 d 99 (47)
Postoperative complications 87 (40)
Infection 35 (16)
Acute respiratory failure 19 (9)
Hemorrhage 8 (4)
Fistula 3 (1)
Adjuvant chemotherapyc 89 (43.6)
Adjuvant radiotherapyd 14 (7.2)
IALT, International Adjuvant Lung Cancer Collaborative Group Trial.
a One missing data.
b Seven missing data.
c Fifteen missing data.
d Twenty-four missing data.
TABLE 3. Types of Chemotherapy Regimens
Type of Regimen Number (%) of Patients (87 Patients)
Cisplatin vinorelbine 19 (21)
Cisplatin gemcitabine 24 (27)
Cisplatin paclitaxel 1 (1)
Cisplatin etoposide 8 (9)
Carboplatin gemcitabine 18 (20)
Carboplatin vinorelbine 3 (3)
Carboplatin paclitaxel 5 (5)
Carboplatin etoposide 3 (3)
Missing data 6 (9)
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operative hospitalization were associated with no adjuvant
chemotherapy (Table 4).
In the multivariate analysis, multiple logistic regression
showed a statistically significant correlation among adjuvant
chemotherapy and age, second cancer, TNM stage, treatment
center, and postoperative hospitalization (Table 5). Older
patients were less likely to receive adjuvant chemotherapy
(OR 0.11, 95% CI, 0.04–0.29). Patients with a previous
cancer were less likely to receive adjuvant chemotherapy
(95% CI, 0.18–0.93; p  0.03). Regarding the TNM stage, a
significant difference was found between stage I and II to III
but not between IA and IB (95% CI, 0.84–6.50; p  0.10).
Patients who had a long postoperative hospital stay were
more likely not to receive adjuvant chemotherapy.
In the Cochran-Armitage tendency test, prescription of
adjuvant chemotherapy increases during the study period:
patients treated during the last 6 months of the study period
(January 2004 to May 2005) seemed more likely to be treated
with adjuvant chemotherapy than patients treated during the
first 6 months of the study period.
Outcome
Several large randomized trials and a pooled analysis
have demonstrated and evaluated the extent of this benefit.
However, in our population, there is no difference in cancer
relapse in patients treated with adjuvant chemotherapy (23 of
87 patients) compared with patients not treated with adjuvant
chemotherapy (21 of 115 patients).
TABLE 4. Univariate Analysis
No Adjuvant
Chemotherapy
(n  115) (%)
Adjuvant
Chemotherapy
(n  87) (%) p
Sex
Male 70 (60.9) 63 (72.4) 0.09
Female 45 (39.1) 24 (27.6)
Age (yr)
60 34 (29.6) 53 (60.9) 0.0001
60–69 28 (24.4) 22 (25.3)
70 53 (46.1) 12 (13.8)
Centre
IGR 33 (28.7) 16 (18.4) 0.0001
Créteil (CHIC) 13 (11.3) 21 (24.1)
Saint Louis (AP-HP) 14 (12.2) 27 (31.0)
Autre 55 (47.8) 23 (26.4)
Center specialized in
thoracic oncology
60 (52.2) 68 (78.2) 0.0001
Histology
Adenocarcinoma 51 (44.4) 41 (47.1) 0.78
Squamous cell
carcinoma
37 (32.2) 24 (27.6)
Autre 27 (23.5) 22 (25.3)
Stage
IA 29 (25.4) 14 (16.1) 0.04
0.005
IB 41 (36.0) 22 (25.3)
II 22 (19.3) 22 (25.3)
III 22 (19.3) 29 (33.3)
Tumor size (mm)a
4 cm 62 (63.9) 42 (53.9) 0.18
4 cm 35 (36.1) 36 (46.2)
Arterial comorbidityb 56 (49.1) 28 (32.2) 0.02
Chronic respiratory
failure
13 (11.3) 13 (14.9) 0.44
Previous cancer 43 (37.4) 19 (21.8) 0.02
Time between IALT
publication and
surgery
6 mo 46 (40.0) 23 (26.4) 0.03
6 mo and 1 yr 33 (28.7) 26 (29.9)
1 yr 36 (31.3) 38 (43.7)
Surgery
Lobectomy  wedge 79 (68.7) 59 (67.8) 0.65
Pneumonectomy 
wedge
19 (16.5) 18 (20.7)
Wedge 17 (14.8) 10 (11.5)
Time between surgery
and discharged
8 d 52 (46.0) 54 (65.1) 0.008
8 d 61 (54.0) 29 (34.9)
Postoperative
complications
51 (44.4) 32 (36.8) 0.28
Radiotherapyc 4 (3.6) 10 (12.5) 0.02
IGR, Institut Gustave Roussy; IALT, International Adjuvant Lung Cancer Collab-
orative Group Trial.
a Twenty-seven missing data.
b One missing data.
c Ten missing data.
TABLE 5. Multivariate Analysis
Odd
Ratio
95% Confidence
Interval p
Sex 0.06
Male 1 — —
Female 0.48 0.22 1.03
Age
60 yr 1 — — 0.0001
60–69 yr 0.35 0.14 0.85
70 yr 0.11 0.05 0.29
Centers
Others 1 — — 0.0003
IGR 1.04 0.42 2.57
Créteil 4.70 1.64 13.37
Saint Louis 7.03 2.45 20.16
Stage
IA 1 — — 0.0007
IB 2.35 0.85 6.51
IIA–IIB 5.35 1.73 16.52
IIIA–IIIB 9.94 3.11 31.78
Previous cancer 0.41 0.18 0.93 0.03
Time between surgery
and discharged
8 d 1 — — 0.03
8 d 0.45 0.22 0.93
IGR, Institut Gustave Roussy.
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DISCUSSION
In our study, we showed that although cisplatin-based
chemotherapy is the standard treatment for patients with early
NSCLC, since 2005: (i) daily practice differs significantly
from standard recommendations, (ii) various factors explain
nonadherence to the recommended standard approach (age,
comorbidity, TNM stage, postoperative complications, and
patient wishes), and (iii) considerably variety chemotherapy
regimens are used for adjuvant therapy in daily practice.
Until recently, surgery alone remained the standard of
care for patients with early-stage NSCLC. The IALT trial was
the first to demonstrate a significant absolute benefit in favor
of cisplatin-based adjuvant chemotherapy. Since then, three
other trials confirmed this result and supported the use of
cisplatin-based adjuvant chemotherapy in daily practice.15
Lack of difference in cancer-relapse patients treated with
adjuvant chemotherapy (23 of 87 patients) compared with
patients not treated with adjuvant chemotherapy (21 of 115
patients) in our series is probably related to a short follow-up
and reduced statistical power (n  87  115). A number of
factors may have contributed to the prescribing and indica-
tions of adjuvant chemotherapy after the publication of the
IALT trial. The prescribing and indications of adjuvant che-
motherapy pose several problems and data on the use of
adjuvant chemotherapy in NSCLC in daily practice are few
and far between. To our knowledge, a population-based
evaluation of the extent to which it has been adopted and the
reasons for poor compliance with guidelines have not been
reported in an European country. Kassam et al.16 recently
published a study on adjuvant chemotherapy in daily practice
in Canada, in patients with completely resected NSCLC
between May 2003 and May 2005.
In our study, we reviewed all the patients treated for
early-stage NSCLC and evaluated the use and administration
of adjuvant chemotherapy after complete surgery in daily
practice after the publication of the IALT trial. Only 43% of
patients were treated with adjuvant chemotherapy. Various
factors were associated with doctors not prescribing this
treatment: age, comorbidities, TNM stage, and postoperative
hospitalization.
Most of these factors are exclusion criteria in clinical
trials. In clinical trial, the selection of population is defined by
inclusion and exclusion criteria, which may result in differ-
ence between patients enrolled in clinical trial and other
patients, and less than 5% of patients are enrolled in clinical
trials in the European Union. A retrospective analysis com-
pared 19,340 patients treated between 1990 and 1997 en-
rolled in clinical trials to the general population of Surveil-
lance, Epidemiology, and End Results. Patients in the clinical
trial were younger with a better performance status and fewer
comorbidities.17
As the elderly population continues to grow, the use of
adjuvant chemotherapy in the elderly will increasingly be-
come important for oncologists in the 21st century. A specific
study is warranted to determine the best treatment for this
population. The median age of patients with NSCLC is 60 to
62 years, whereas the median age for newly diagnosed
NSCLC is 70 years. More than 50% of patients are older than
65 years and 30 to 40% are older than 70 years. Elderly
patients have been underrepresented in clinical trials, and
patients are often given less intense and possibly inferior
standard therapy because of their age. In our study, 67
patients who had undergone complete surgery were older
than 70 years, and 15 of them were older than 80 years.
Adjuvant chemotherapy was not prescribed for these patients
because of their age. Recent data show that the fittest elderly
patients derive a benefit from standard adjuvant chemother-
apy regimens in an equivalent manner to their younger
counterparts. In the JBR.10 trial, elderly patients enjoyed the
same benefit as younger patients.18,19 Although elderly pa-
tients receive less chemotherapy, adjuvant chemotherapy im-
proves survival in patients older than 65 years with accept-
able toxicity. Therefore, adjuvant chemotherapy should not
be withheld from elderly patients.20
Postoperative hospitalizations and complications are a
major issue. In all adjuvant chemotherapy clinical trials,
patients should begin adjuvant therapy within 4 to 8 weeks of
surgery. In our study, 88 patients had experienced postoper-
ative complications, which led to a long hospital stay. The
duration of hospitalization had an impact on doctors not
prescribing adjuvant chemotherapy. There are no clear data
on the benefit of adjuvant chemotherapy beyond 2 months
after surgery.
The presence of both significant comorbidities and a
low performance status are important prognostic factors in
lung cancer.21,22 In our study, 27 patients had severe comor-
bidity contraindicating adjuvant therapy. The evaluation of
comorbidity should be recommended to assess the benefit/
risk ratio of medical anticancer therapies. Chemotherapeutic
agents with a different toxicity profile compared with cispla-
tin could be considered in this setting.
Large differences in prescribing of adjuvant chemother-
apy exist between the different centers. To our knowledge,
there is no clear and simple reason to explain difference in
compliance with guidelines.
Finally, patients may refuse to follow medical recom-
mendations. In our study, eight patients refused adjuvant
chemotherapy. The differences of opinion between patients
and physicians could be explained by fear of treatment, or a
lack of understanding of the benefit/risk ratio. There are tools
designed to help patients choose between different options
(c.f., adjuvantonline) in the case of breast and colon cancer.23
This system could be implemented in lung cancer practice. A
recent study showed that compliance with postoperative ad-
juvant chemotherapy in NSCLC in the JBR.10 Intergroup
trial was associated with the extent of surgery, gender, and
age in the multivariate analysis.24 In addition, patients en-
rolled in Canada were found to be more likely to fail to
complete chemotherapy due to refusal of therapy than those
in America. This difference could be due to a different
perception of the benefit of adjuvant chemotherapy. Kassam
et al.16 also showed that in Canada, half of the patients
referred for adjuvant chemotherapy to a medical oncologist
declined treatment even when it was recommended to them.
In our study, only eight patients declined adjuvant chemo-
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therapy, which suggests a different mentality between Europe
and the United States.
One explanation for the early interruption of adjuvant
chemotherapy is chemotherapy-related toxicity. Most of the
clinical trials with adjuvant chemotherapy reported grade 3 to
4 toxicities in 20% of cases and less than 1% of toxic deaths.
In our study, 25 patients (28%) had experienced grade 3 to 4
hematological and nonhematological toxicities. Two of 87
patients treated with adjuvant chemotherapy had died of
chemotherapy-related toxicities. Despite the toxicity issue,
our data show that more than 75% of patients had received all
the cycles of adjuvant chemotherapy, thus confirming the
feasibility of this treatment in daily practice.
Changes in practice over time must also be taken into
consideration. The first trial to demonstrate the benefit of
adjuvant chemotherapy was the IALT published in 2004. Our
study evaluated all the patients treated between January 2004
and May 2005 and showed a trend toward a change in
adjuvant chemotherapy prescribing patterns according to
time. A recent article showed that taxanes were increasingly
used in the adjuvant setting for patients with breast cancer
following the presentation of CALCB 9344 during the 1999
American Society of Cancer Oncology meeting.25 Several
factors could explain the rapidity of changes in practice: the
extent of the clinical benefit, strong evidence, other results of
trials, alternative options, etc.26 Kassam et al.16 showed that
indications for adjuvant chemotherapy doubled between May
2003 and June 2004 after publication of the IALT and JBR.10
trials.
All randomized clinical trials evaluated adjuvant che-
motherapy using cisplatin-based chemotherapy or Uracil-
Tegafur.27 The only trial that used carboplatin was negative.28
In our study, more than eight protocols were used, and 18
patients were treated with carboplatin and gemcitabine. This
variety in regimens could be explained by the fact that similar
results were obtained with different cisplatin-based doublets
in the metastatic setting. Moreover, there was only one
positive randomized trial in 2004 (IALT trial). Further large
randomized trials confirm that cisplatin-based chemotherapy
is the only active regimen in adjuvant setting. Nevertheless, it
is not possible to extrapolate the efficacy of regimens in the
metastatic setting to the adjuvant setting in the absence of
prospective trials, and guidelines are necessary as in breast
cancer.29,30 It is possible that adjuvant chemotherapy regi-
mens are now more standardized.
In 2007, Kassam et al.16 published a retrospective study
about adjuvant chemotherapy in daily practice in Canada
between May 2003 and May 2005. They showed that indi-
cations for adjuvant chemotherapy doubled during this period
and several reasons for the nonuse of adjuvant chemotherapy
were the TNM stage (37%), patient refusal (18%), comor-
bidities, postoperative complications (10%), and advanced
age (2%). In our study, most patients had not received
adjuvant chemotherapy because of age, TNM stage, comor-
bidities, and postoperative hospitalizations, which confirm
the previous results. A few patients refused adjuvant chemo-
therapy, which could suggest a difference in the patient-
doctor relationship between Canada and Europe.
CONCLUSIONS
Randomized trials recently demonstrated a clinical ben-
efit with adjuvant chemotherapy as the standard of care for
patients with early-stage NSCLC. Nevertheless, such treat-
ment is used very heterogeneously in daily practice because
of patient characteristics (age, comorbidity, and postoperative
hospitalization), drug prescribing patterns (period of treat-
ment), and tumor characteristics (TNM stage and histology),
as demonstrated in our study. This study showed that several
clinical factors could explain the nonadherence to adjuvant
chemotherapy guidelines in patients with NSCLC. Moreover,
very different chemotherapy regimens are being prescribed in
this setting during the study period. The use of adjuvant
chemotherapy in patients with NSCLC warrants investigation
because of differences between daily practice and guidelines.
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